EULAR Updates Behçet’s Syndrome Recommendations - Takeaway - MDSpire
From the Journals
Clinical Guidelines

EULAR Updates Behçet’s Syndrome Recommendations

EULAR releases updated recommendations supporting earlier biologic use in patients with eye, vascular, and nervous system involvement

Share

  • 1

    Updated recommendations from the European Alliance of Associations for Rheumatology for Behçet's syndrome management.

  • 2

    Emphasis on early biologic use for severe organ involvement.

  • 3

    Five overarching principles and 12 organ-specific recommendations.

  • 4

    Colchicine remains first-line for mucocutaneous lesions.

  • 5

    Combination therapy recommended for sight-threatening uveitis.

  • 6

    Multi-organ assessment and individualized treatment approach required.

  • 7

    High agreement scores among task force members on recommendations.

Original Source(s)

EULAR Updates Behçet’s Syndrome Recommendations

  • by Kathryn Wighton

  • April 1, 2026

Related Content

RA App Overestimates Active Disease

Self-reported joint counts showed modest agreement with physician assessments and tended to overestimate active disease in a community-based study

Low DLCO/SB Linked to Faster SSc Progression

Lower gas transfer at baseline was associated with higher unadjusted progression rates and shorter time to transition, though multivariable analysis did not identify independent predictors

TENS Added to Physical Therapy Lowers Fibromyalgia Pain

Adjunctive transcutaneous electrical nerve stimulation improves movement-evoked pain and fatigue in pragmatic trial